Thymic carcinoma (TC), the rarer among Thymic Epithelial Tumors (TET), occur with an incidence rate of 0.2-0.5/million/yr. Difficulties in the evaluation of molecular aspects derive from the extreme rarity of these tumors. The Squamous cell carcinoma (SQCC) is the most frequently analyzed, however the other rarer histotypes could differ both in molecular pathogenesis and in clinical behaviour. The Cancer Genome Atlas Thymoma study (TCGA-THYM) in a series of ten TC cases including four SQCC, four undifferentiated carcinoma and both one large cell neuroendocrine carcinoma as well as one TC, NOS, identified a few genes rarely mutated, including KIT, HRAS, NRAS and TP53, reflecting the low mutational burden of these tumors (1).

Novel biomarkers for thymic carcinoma / Casini, B.; Gallo, E.; Melis, E.; Cecere, F.; Laquintana, V.; Cerasoli, V.; Facciolo, F.; Pescarmona, E.; Fazi, F.; Marino, M.. - In: JOURNAL OF THORACIC ONCOLOGY. - ISSN 1556-0864. - 14:10S(2019), pp. S169-S170. (Intervento presentato al convegno IASLC 2019 World Conference on Lung Cancer tenutosi a Barcelona, Spain) [10.1016/j.jtho.2019.08.338].

Novel biomarkers for thymic carcinoma

Pescarmona, E.;Fazi, F.;
2019

Abstract

Thymic carcinoma (TC), the rarer among Thymic Epithelial Tumors (TET), occur with an incidence rate of 0.2-0.5/million/yr. Difficulties in the evaluation of molecular aspects derive from the extreme rarity of these tumors. The Squamous cell carcinoma (SQCC) is the most frequently analyzed, however the other rarer histotypes could differ both in molecular pathogenesis and in clinical behaviour. The Cancer Genome Atlas Thymoma study (TCGA-THYM) in a series of ten TC cases including four SQCC, four undifferentiated carcinoma and both one large cell neuroendocrine carcinoma as well as one TC, NOS, identified a few genes rarely mutated, including KIT, HRAS, NRAS and TP53, reflecting the low mutational burden of these tumors (1).
2019
IASLC 2019 World Conference on Lung Cancer
04 Pubblicazione in atti di convegno::04d Abstract in atti di convegno
Novel biomarkers for thymic carcinoma / Casini, B.; Gallo, E.; Melis, E.; Cecere, F.; Laquintana, V.; Cerasoli, V.; Facciolo, F.; Pescarmona, E.; Fazi, F.; Marino, M.. - In: JOURNAL OF THORACIC ONCOLOGY. - ISSN 1556-0864. - 14:10S(2019), pp. S169-S170. (Intervento presentato al convegno IASLC 2019 World Conference on Lung Cancer tenutosi a Barcelona, Spain) [10.1016/j.jtho.2019.08.338].
File allegati a questo prodotto
File Dimensione Formato  
Casini_Novel_2019.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 215.34 kB
Formato Adobe PDF
215.34 kB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1389027
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 1
social impact